HUTCHMED (China) Limited discovers, develops and markets targeted immunotherapies and therapies for cancer and immune diseases globally. The company is headquartered in Central, Hong Kong.
| Revenue (TTM) | $549.12M |
| Gross Profit (TTM) | $73.10M |
| EBITDA | $-20.52M |
| Operating Margin | 0.31% |
| Return on Equity | 1.46% |
| Return on Assets | -1.24% |
| Revenue/Share (TTM) | $3.19 |
| Book Value | $7.25 |
| Price-to-Book | 1.68 |
| Price-to-Sales (TTM) | 3.86 |
| EV/Revenue | 1.618 |
| EV/EBITDA | 1.71 |
| Quarterly Earnings Growth (YoY) | -96.50% |
| Quarterly Revenue Growth (YoY) | 0.20% |
| Shares Outstanding | $173.81M |
| Float | $104.59M |
| % Insiders | 0.01% |
| % Institutions | 2.69% |
Volatility is currently contracting
AstraZeneca halts a phase III NSCLC study for volrustomig after data show that the regimen is unlikely to meet key survival goals, while other lung cancer trials shine.
Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) shares rose 4% to 192p after the biopharmaceutical company reported positive top-line results from a late-stage global trial of its lung cancer drug savolitinib. The Phase III SAFFRON study tested savolitinib, sold as Orpathys, in combination with AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) Tagrisso in patients with a form of non-small cell lung cancer whose disease had worsened despite treatment.
— First global Phase III trial to show significant progression-free and overall survival benefits in this setting —
HUTCHMED (China) Limited (HCM) Q2 2026 Earnings Call Transcript
HUTCHMED NASDAQ: HCM reported first-half 2026 oncology revenue of $162 million, including $121 million in product revenue, as growth in China and expanding international sales of FRUZAQLA supported results. The company maintained its full-year oncology revenue guidance of $330 million to $415 million and said it remained profitable during the period.
First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China First selective MET inhibitor approved for patients with MET-amplified advanced gastric cancer or gastroesophageal junction adenocarcinoma in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 30, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX:13) will announce its interim results for the six months ended June 30, 2026 on Thursday, July 30, 2026 at 7:00 am Eastern Daylight Time (EDT) / 12:00 noon British Summer Time (BST) / 7:00 pm Hong Kong Time (HKT).
SEATTLE--(BUSINESS WIRE)--Syndio, the Decision Intelligence for Pay company, today announced the acquisition of Embrace.ai, an agentic AI company built to deploy AI-driven automation across business workflows. The full Embrace.ai team, led by founders and enterprise software veterans Derek Butts and Seth Halpern, will join Syndio's product and go-to-market organization. The acquisition bolsters the Syndio team with deep experience across enterprise human capital management (HCM), large-scale so.
– No relationship observed between EDG-7500 exposure and LVEF; no LVEF reductions below 50% – – Consistent and clinically meaningful improvements observed in echocardiogram parameters, biomarkers, symptoms and functional status across obstructive and nonobstructive HCM – – EDG-7500 administration continued to be generally well tolerated – – Company to host webcast today at 8:30 a.m. Eastern Time – BOULDER, Colo.
LAS VEGAS, June 15, 2026 (GLOBE NEWSWIRE) -- Connect for Partners – isolved®, a provider of human capital management (HCM) solutions that help organizations recruit, retain and elevate their workforce, proudly recognized top-performing partners during its annual isolved Connect for Partners. Now in its ninth year, Connect for Partners has grown into the premier gathering for the isolved partner community bringing together hundreds of HR and benefits providers for immersive product deep-dives, peer connection and forward-looking strategy sessions designed to sharpen competitive edge and accelerate client outcomes.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on HCM and any ticker you trade — then tracks every position and per-strategy win rate.
